Regulating Private Equity in Health Care: A Strategic Policy Agenda

Why It Matters

Unchecked PE activity threatens cost inflation, care quality, and market competition, making robust regulation essential for a sustainable health‑care system.

Key Takeaways

• PE invested ~ $1 trillion in U.S. health care over past decade
• Antitrust and reporting rules lag, with >90% of deals unreported in 2022
• States are adopting “mini‑HSR” laws; 15+ have passed them
• Proposed reforms include health‑care‑specific PE law, alternative payment models, federal‑state registry

Pulse Analysis

The surge of private‑equity capital into American health‑care has outstripped the regulatory tools designed to monitor it. While the Hart‑Scott‑Rodino Act mandates disclosure for transactions above a certain threshold, the rapid proliferation of PE‑backed roll‑ups—spanning long‑term care, specialty clinics, and hospital systems—has left a transparency gap. Empirical studies link these acquisitions to higher payer costs, mixed quality outcomes, and staffing cuts, underscoring the urgency for policy action. As the sector continues to attract near‑trillion‑dollar inflows, regulators must reconcile financial incentives with patient‑centered goals.

State governments have begun to fill the vacuum, enacting “mini‑HSR” statutes that lower reporting thresholds and empower attorneys general to scrutinize deals. Over 15 states, including New York and Oregon, now require detailed filings, creating a patchwork of oversight that nonetheless signals growing political will. Concurrently, more than 70 bills across 25 states aim to curb anticompetitive behavior, strengthen corporate‑practice‑of‑medicine rules, and enhance patient‑protection statutes. These initiatives illustrate a shift from reactive enforcement to proactive governance, yet the lack of a unified national framework hampers consistency and data sharing.

Looking ahead, a coordinated federal‑state strategy could harmonize reporting standards, expand antitrust criteria to include cost and quality metrics, and introduce health‑care‑specific PE legislation. Alternative payment models—such as bundled payments and capitation—would align investor returns with clinical outcomes, reducing incentives for overutilization. A national registry, modeled on European transparency mandates, would provide researchers and policymakers with real‑time insight into ownership structures and performance. By marrying rigorous oversight with incentive‑compatible financing, the U.S. can harness private capital to innovate while safeguarding the accessibility and quality of care.